← Back to Search

Cleanser

Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora

N/A
Waitlist Available
Research Sponsored by NovaBay Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed on visit 1(day 1), visit 2 (day 11) and visit 3 (day 18)

Summary

This study is designed to evaluate the effect of Novabay iLid Cleanser, as compared to its Vehicle, on the ocular skin flora. In the pre-randomization phase, subjects will receive a single application of open-label NovaBay iLid Cleanser. In the randomization phase of Stages 1 and 2, subjects will self-treat with masked Investigational Product twice daily for ten (10) days.

Eligible Conditions
  • Blepharitis
  • Sebaceous Cyst
  • Sebaceous Gland Dysfunction

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed on visit 1(day 1), visit 2 (day 11) and visit 3 (day 18)
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed on visit 1(day 1), visit 2 (day 11) and visit 3 (day 18) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Microbiological efficacy
Secondary study objectives
Ocular Signs

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: iLid Cleanser (Avenova)Active Control1 Intervention
iLid Cleanser - applied 2 times per day for 10 days
Group II: iLid Cleanser VehiclePlacebo Group1 Intervention
iLid Cleanser Vehicle - applied 2 times per day for 10 days

Find a Location

Who is running the clinical trial?

NovaBay Pharmaceuticals, Inc.Lead Sponsor
9 Previous Clinical Trials
1,426 Total Patients Enrolled
1 Trials studying Blepharitis
14 Patients Enrolled for Blepharitis
David W. Stroman, Ph.D.Study DirectorNovaBay Pharmaceuticals, Inc.
1 Previous Clinical Trials
217 Total Patients Enrolled
~9 spots leftby Jan 2026